GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 07 2024 - 12:00PM
Business Wire
- Under its COiMMUNITY Initiative, GSK is committing up to $2
million in 2024 to support adult immunization and health
equity
- GSK launches new patient-centered resources to facilitate
provider-patient vaccination conversations and
recommendations
- New Q3 2023 Vaccine Track data show potential return of
adult immunization rates to pre-pandemic levels, largely driven by
an increase in Medicare and Medicaid claims
GSK plc (LSE/NYSE: GSK) today announced additional funding and
new data and resources under the COiMMUNITY Initiative to help
achieve higher adult vaccination rates and health equity in the US
and address ongoing barriers to adult immunization. The COiMMUNITY
Initiative complements recent industry and regulatory efforts to
expand and improve adult vaccine availability, coverage and
access.
Rob Truckenmiller, Senior Vice President, Head of US
Vaccines, GSK, said: “Unlocking the power of prevention
requires collaboration across the healthcare and public health
ecosystem, as well as strong financial commitments. That’s why we
are doubling down on our COiMMUNITY Initiative grants, sharing
exciting new adult immunization data and launching new resources to
help remove traditional barriers to vaccination.”
Increased Funding
In 2024, GSK is giving up to $2 million in COiMMUNITY Initiative
grants to support local, state and national non-profits and
community-based groups focused on improving adult immunization
rates and supporting health equity across the US. Last year, 10
projects received COiMMUNITY Initiative grants ranging from $50,000
to $175,000 each – for a total of $1 million – to support their
ambitious and actionable work. Recipients have shared immediate
successes from programs strengthened by these grants, such as:
Seth Ginsberg, Co-Founder and President,
Global Healthy Living Foundation said: “Thanks to GSK’s
support, we launched a nationwide bilingual campaign to help
improve education around respiratory vaccination among
multigenerational Hispanic/Latino communities. These communities
have been disproportionately affected by infectious diseases, and
often face barriers navigating the US healthcare system."
Deb Brown, Chief Mission Officer, American
Lung Association said: “Our COiMMUNITY-funded local outreach is
helping build vaccine confidence in rural Kentucky. We’re currently
assessing adult immunization gaps and creating culturally competent
educational materials to be disseminated through community leaders.
Our hope is that this program could serve as a model for increasing
vaccine equity in other rural areas.”
Eligible organizations interested in applying for 2024 grant
funding should respond to the Request for Proposals on
gskfunding.com and address their response to the COiMMUNITY
Initiative. GSK will review and approve grant proposals on a
rolling basis according to set principles and criteria until
mid-November of 2024.
New Resources
A recent GSK survey found that many adults ages 50-79 are
unfamiliar with the vaccines recommended for them, and physicians
indicate that most adults are unlikely to receive many of the
vaccines they recommend. GSK is equipping healthcare providers and
their patients with simple tools to spur action and follow through
on vaccination. These two new resources include: a patient vaccine
log and EasyVax™, a mobile vaccine scheduler. The vaccine log helps
healthcare providers and patients track year-round vaccinations and
identify potential immunization gaps. EasyVax helps providers
streamline the pharmacy vaccine referral process, empowering
patients to quickly locate and schedule retail vaccine appointments
from anywhere, including a provider’s office at the point of
recommendation.
GSK will also continue to share new resources, tools and best
practices in adult vaccine confidence and delivery via interactive
webinars.
New Data
According to Vaccine Track data published today, in Q1-Q3 2023,
average adult monthly non-flu vaccination rates are 1% higher than
the same time period in 2019. This is the first-time data show
average adult vaccination rates are higher than pre-pandemic
levels. The data, which captures claims through Q3 2023, suggest
that an uptick in Medicare and Medicaid vaccination claims drove
the increase, as commercial claims were 4% lower in Q1-Q3 2023
compared to the same time period in 2019.
While it is too early to assess how much of the increase in
average monthly claims is a result of the Inflation Reduction Act
(IRA) versus seasonality or other factors, the IRA’s elimination of
adult vaccination cost-sharing under Medicare – extended to
Medicaid-enrolled adults in October 2023 – appears to be a partial
driver of the apparent recovery from the pandemic-era decline.
About Vaccine Track
Vaccine Track is a comprehensive platform developed by GSK, in
collaboration with IQVIA, for use by public health officials,
industry leaders and medical professionals to strengthen
vaccination data transparency, raise awareness and publicly share
vaccination trends. Containing comprehensive claims data about
routine adult (age 19+) vaccines, Vaccine Track currently spans
information from January 2019 to September 2023 and will be updated
on a quarterly basis. Information is sourced from medical claims
data and longitudinal prescription data, both of which are
de-identified for research purposes. Medical claims data is
collected from services performed in physicians’ offices.
Longitudinal prescription data is sourced from retail and mail
pharmacies as well as long-term care facilities. Vaccines
administered in institutional or hospital settings, as well as
through certain other settings or programs, are not accounted for
in projections.
Vaccine Track is open to public and private stakeholders,
welcoming the opportunity to potentially integrate and host
additional data and viewpoints on adult vaccination trends. Data
integration is subject to a Data Licensing Agreement.
About GSK
GSK is a global biopharma company with a purpose to unite
science, technology, and talent to get ahead of disease together.
Find out more at gsk.com.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
“Risk factors” in the company's Annual Report on Form 20-F for
2022, and Q4 Results for 2023.
Registered in England & Wales: No. 3888792
Registered Office: 980 Great West Road Brentford,
Middlesex TW8 9GS
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306698092/en/
GSK inquiries Media: Kathleen Quinn +1 202 603 5003
(Washington DC) Alison Hunt +1 540 742 3391 (Washington DC)
Investor Relations: Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024